FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005613002> ?p ?o ?g. }

• W2005613002 endingPage "1179" @default.
• W2005613002 startingPage "1173" @default.
• W2005613002 abstract "The aim of this study was to determine the effect of several antidiabetic agents on insulin-stimulated glycogen synthesis, as well as on mRNA expression.Cultured primary human skeletal myotubes obtained from six healthy subjects were treated for 4 or 8 days without or with glucose (25 mmol/l), insulin (400 pmol/l), rosiglitazone (10 micromol/l), metformin (20 micromol/l) or the AMP-activated kinase activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) (200 micromol/l). After this, insulin-stimulated glycogen synthesis was determined. mRNA levels of the glucose transporters GLUT1 and GLUT4, the peroxisomal proliferator activator receptor gamma (PPAR gamma) co-activator 1 (PGC1) and the myocyte-specific enhancer factors (MEF2), MEF2A, MEF2C and MEF2D were determined using real-time PCR analysis after 8 days exposure to the various antidiabetic agents.Insulin-stimulated glycogen synthesis was significantly increased in cultured human myotubes treated with insulin, rosiglitazone or metformin for 8 days, compared with non-treated cells. Furthermore, an 8-day exposure of myotubes to 25 mmol/l glucose impaired insulin-stimulated glycogen synthesis. In contrast, treatment with AICAR was without effect on insulin-mediated glycogen synthesis. Exposure to insulin, rosiglitazone or metformin increased mRNA expression of PGC1 and GLUT4, while AICAR or 25 mmol/l glucose treatment increased GLUT1 mRNA expression. Metformin also increased mRNA expression of the MEF2 isoforms.Enhanced insulin-stimulated glycogen synthesis in human skeletal muscle cell culture coincides with increased GLUT4 and PGC1 mRNA expression following treatment with various antidiabetic agents. These data show that chronic treatment of human myotubes with insulin, metformin or rosiglitazone has a direct positive effect on insulin action and mRNA expression." @default.
• W2005613002 created "2016-06-24" @default.
• W2005613002 creator A5000008605 @default.
• W2005613002 creator A5014267586 @default.
• W2005613002 creator A5041729124 @default.
• W2005613002 creator A5068081328 @default.
• W2005613002 creator A5069397710 @default.
• W2005613002 creator A5089906779 @default.
• W2005613002 date "2005-04-30" @default.
• W2005613002 modified "2023-10-12" @default.
• W2005613002 title "Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1" @default.
• W2005613002 cites W1527476004 @default.
• W2005613002 cites W1582691127 @default.
• W2005613002 cites W1969554900 @default.
• W2005613002 cites W1974550672 @default.
• W2005613002 cites W1987940856 @default.
• W2005613002 cites W1988642111 @default.
• W2005613002 cites W2002928794 @default.
• W2005613002 cites W2008632158 @default.
• W2005613002 cites W2010803961 @default.
• W2005613002 cites W2011182719 @default.
• W2005613002 cites W2012873493 @default.
• W2005613002 cites W2022721465 @default.
• W2005613002 cites W2038588802 @default.
• W2005613002 cites W2046950599 @default.
• W2005613002 cites W2048080161 @default.
• W2005613002 cites W2048328229 @default.
• W2005613002 cites W2049481764 @default.
• W2005613002 cites W2060118222 @default.
• W2005613002 cites W2064018079 @default.
• W2005613002 cites W2069929383 @default.
• W2005613002 cites W2070892520 @default.
• W2005613002 cites W2071631797 @default.
• W2005613002 cites W2073462688 @default.
• W2005613002 cites W2075171810 @default.
• W2005613002 cites W2077199902 @default.
• W2005613002 cites W2077230920 @default.
• W2005613002 cites W2084321300 @default.
• W2005613002 cites W2087136121 @default.
• W2005613002 cites W2092801459 @default.
• W2005613002 cites W2093201995 @default.
• W2005613002 cites W2094564248 @default.
• W2005613002 cites W2100514340 @default.
• W2005613002 cites W2103143313 @default.
• W2005613002 cites W2114424910 @default.
• W2005613002 cites W2118504596 @default.
• W2005613002 cites W2122338601 @default.
• W2005613002 cites W2122649002 @default.
• W2005613002 cites W2123521914 @default.
• W2005613002 cites W2128497056 @default.
• W2005613002 cites W2134705701 @default.
• W2005613002 cites W2140068086 @default.
• W2005613002 cites W2146845495 @default.
• W2005613002 cites W2147612813 @default.
• W2005613002 cites W2162081654 @default.
• W2005613002 cites W2164134117 @default.
• W2005613002 cites W2167399678 @default.
• W2005613002 cites W2179834582 @default.
• W2005613002 cites W2185466449 @default.
• W2005613002 cites W2407093535 @default.
• W2005613002 doi "https://doi.org/10.1007/s00125-005-1741-3" @default.
• W2005613002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15864539" @default.
• W2005613002 hasPublicationYear "2005" @default.
• W2005613002 type Work @default.
• W2005613002 sameAs 2005613002 @default.
• W2005613002 citedByCount "76" @default.
• W2005613002 countsByYear W20056130022012 @default.
• W2005613002 countsByYear W20056130022013 @default.
• W2005613002 countsByYear W20056130022014 @default.
• W2005613002 countsByYear W20056130022015 @default.
• W2005613002 countsByYear W20056130022016 @default.
• W2005613002 countsByYear W20056130022017 @default.
• W2005613002 countsByYear W20056130022018 @default.
• W2005613002 countsByYear W20056130022020 @default.
• W2005613002 countsByYear W20056130022021 @default.
• W2005613002 countsByYear W20056130022022 @default.
• W2005613002 countsByYear W20056130022023 @default.
• W2005613002 crossrefType "journal-article" @default.
• W2005613002 hasAuthorship W2005613002A5000008605 @default.
• W2005613002 hasAuthorship W2005613002A5014267586 @default.
• W2005613002 hasAuthorship W2005613002A5041729124 @default.
• W2005613002 hasAuthorship W2005613002A5068081328 @default.
• W2005613002 hasAuthorship W2005613002A5069397710 @default.
• W2005613002 hasAuthorship W2005613002A5089906779 @default.
• W2005613002 hasBestOaLocation W20056130021 @default.
• W2005613002 hasConcept C109384507 @default.
• W2005613002 hasConcept C126322002 @default.
• W2005613002 hasConcept C134018914 @default.
• W2005613002 hasConcept C161573976 @default.
• W2005613002 hasConcept C170493617 @default.
• W2005613002 hasConcept C185592680 @default.
• W2005613002 hasConcept C187345961 @default.
• W2005613002 hasConcept C192118531 @default.
• W2005613002 hasConcept C2776188179 @default.
• W2005613002 hasConcept C2777499176 @default.
• W2005613002 hasConcept C2777952866 @default.
• W2005613002 hasConcept C2778150266 @default.
• W2005613002 hasConcept C2779306644 @default.

• next